Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Lipidor

Less than 1K followers
All
Press releases
3rd party
ShowingAll content types
Regulatory press release5/25/2025, 3:25 PM

Lipidor ansöker om konkurs

Lipidor
Regulatory press release5/25/2025, 3:25 PM

Lipidor applies for bankruptcy

Lipidor
Regulatory press release5/24/2025, 10:40 AM

Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis

Lipidor

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/24/2025, 10:40 AM

Lipidor meddelar idag negativt resultat från bolagets kliniska fas III-studie av AKP02G2 mot psoriasis

Lipidor
Press release5/19/2025, 6:30 AM

Lipidor tillkännager databasstängning (”Database Lock”) i sin kliniska Fas III-studie med psoriasiskandidaten AKP02G2

Lipidor
Press release5/19/2025, 6:30 AM

Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2

Lipidor
Regulatory press release5/9/2025, 12:25 PM

Lipidor AB (publ) offentliggör årsredovisning för 2024

Lipidor
Regulatory press release5/9/2025, 12:25 PM

Lipidor AB (publ) publishes annual report for 2024

Lipidor
Press release3/17/2025, 7:30 AM

Lipidor meddelar att alla patienterna har rekryterats till den pågående Fas III-studien

Lipidor
Press release3/17/2025, 7:30 AM

Lipidor announces all patients enrolled in ongoing Phase III study

Lipidor
Regulatory press release2/28/2025, 7:30 AM

Lipidor AB (publ) offentliggör bokslutskommuniké för 2024

Lipidor
Regulatory press release2/28/2025, 7:30 AM

Lipidor AB (publ) publishes year-end report for 2024

Lipidor
Press release1/21/2025, 7:00 AM

Lipidor meddelar att hälften av patienterna har rekryterats till den pågående Fas III-studien

Lipidor
Press release1/21/2025, 7:00 AM

Lipidor announces half of patients enrolled in ongoing Phase III study

Lipidor
Regulatory press release12/3/2024, 7:00 AM

Lipidor presenterar valberedningen

Lipidor
Regulatory press release12/3/2024, 7:00 AM

Lipidor presents Nomination Committee

Lipidor
Press release11/20/2024, 7:00 AM

Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"

Lipidor
Press release11/20/2024, 7:00 AM

Lipidor publicerar vd-ord för kvartalet – ”studieresultat väntas vid slutet av Q1 2025”

Lipidor
Press release9/24/2024, 4:30 PM

Lipidor meddelar att den första patienten har rekryterats till Fas III-studien med AKP02G2 för topikal behandling av psoriasis

Lipidor
Press release9/24/2024, 4:30 PM

Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

Lipidor
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.